logo

For the Inventor, By the Inventor

Dueren, Germany

Sven Kühnert

This inventor holds 21 USPTO granted patents and 4 published patent applications and 23 EPO patents, primarily in Pharmaceutical Modulators. Top assignees: Gruenenthal Gmbh, Grunenthal Gmbh. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sven Kühnert. Retrieved from https://idiyas.com/inventor/sven-kühnert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 4.8

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 38(Granted Patents)


Company Filing History:

goldMedal14 out of 361 
 
Gruenenthal Gmbh
 patents
silverMedal7 out of 107 
 
Grunenthal Gmbh
 patents

Years Active: 2011-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
KCNQ2/3 Modulators
Pharmaceuticals
Nicotinamides
Carboxamides
Aminoquinolines
Drug Development
Receptor Regulation
Thiazoles
Propiolic Acid Amides
Heteroquinolines
Dihydroisoquinolines
21 patents (USPTO):Explore Patents
1. 9775843 - Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders (2017-10-03),
2. 9284286 - Specific carboxamides as KCNQ2/3 modulators (2016-03-15),
3. 9278103 - Substituted 6-amino-nicotinamides as KCNQ2/3 modulators (2016-03-08),
4. 9248122 - Heteroquinoline-3-carboxamides as KCNQ2/3 modulators (2016-02-02),
5. 9168259 - Substituted 6-amino-nicotinamides as KCNQ2/3 modulators (2015-10-27),
6. 9073862 - Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators (2015-07-07),
7. 8653102 - Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators (2014-02-18),
8. 8653101 - Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators (2014-02-18),
9. 8618129 - Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators (2013-12-31),
10. 8586755 - Substituted nicotinamides as KCNQ2/3 modulators (2013-11-19),
11. 8552200 - Substituted 6-amino-nicotinamides as KCNQ2/3 modulators (2013-10-08),
12. 8470852 - Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators (2013-06-25),
13. 8445512 - Substituted quinoline-3-carboxamides as KCNQ2/3 modulators (2013-05-21),
14. 8399673 - Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators (2013-03-19),
15. 8367700 - Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators (2013-02-05),

Title: Sven Kühnert: Innovator in Medicinal Chemistry from Düren, DE

Introduction

Sven Kühnert, based in Düren, Germany, is a prominent inventor with a remarkable portfolio of 21 patents. His innovative contributions predominantly lie in the field of medicinal chemistry, where he focuses on the treatment of various diseases and disorders.

Latest Patents

Among Sven Kühnert's latest patents are significant advancements in the treatment and prophylaxis of diseases mediated by the Translocator Protein (TSPO). One of these inventions relates to certain compounds that aim to tackle TSPO mediated diseases and disorders. Additionally, he has developed specific carboxamides functioning as KCNQ2/3 modulators. This invention encompasses not only the compounds but also the processes for their preparation, as well as the medicaments that utilize them.

Career Highlights

Sven has worked at Gruenenthal GmbH, a company known for its dedication to innovative medical solutions. His experience there has helped to refine his expertise in medicinal development and drug discovery. His commitment to advancing healthcare solutions is reflected in his extensive patent filings.

Collaborations

Throughout his career, Sven Kühnert has collaborated with notable peers, including Gregor Bahrenberg and Wolfgang Schröder. These collaborations highlight the importance of teamwork and shared expertise in fostering innovation and achieving breakthroughs in medicinal chemistry.

Conclusion

Sven Kühnert stands out as a key figure in the realm of medicinal innovations, especially with his proven track record of patents that contribute significantly to modern medicine. His ongoing work promises to play a vital role in addressing complex health issues linked to TSPO and KCNQ2/3 pathways. As he continues to innovate, the medical community eagerly anticipates the potential impact of his inventions on patient care and treatment methodologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…